This was my personal scientific driver after I became so bearish regarding financing, due to the then upcoming Paulson rounds. I quite received the heated hate in this forum and SP trickled down.
Now we are already within the last financing round for BLA approval plus having a few important catalysts in front of us (TNBC, BLA completion, ..).
I know, BLA 1st stage filing and the above CD03 Mono data didn't yet move the stock above the Warrant threshold.
Financing as of now still sucks and is the necessary evil. But it is almost completed and PRO 140 has a much better evidence based support than 6 month ago, thanks to the increased dosage in the completed Monotherapy trial and the said findings about the VL rebound (flu etc, no tropism change).
Possible that within communicated completed financing goal the SP shall finally appreciate. This could be another catalyst itself.
I agree Gestalt, this is not just about Nader - of course not. CEO + BOD is one team.
FWIW, yes, me and friends are very optimistic now and buying in. We are roughly 1/3 above the BB bottom from its top-bottom range, may or may not hit it - already good enough for accumulation.
May the licensing / partnering effort come to fruition, patients, shareholders and company has truly earned it.
PS: Besides RGSE as mentioned in previous post, there is also GSAT now - 100% above offering price while 25M shares are still purchased and dumped for said 100% profit. And none of these companies sell anything of unique interest. None of them serve an unmet need.
Market Data 
Markets 
AI
